The NCRI Cancer Conference is the UK's largest forum showcasing the latest advances in cancer research and attracting over 1,500 delegates each year. The Conference provides a platform for researchers, clinicians, people affected by cancer and industry representatives to come together to discuss, present and showcase high-quality research.
With more than 500 presentations - including the latest cancer research from around the world - the Conference will cover the whole cancer field, from epidemiology and research in the lab, to trials of new treatments and quality of life studies.
The Conference is run by the National Cancer Research Institute, a UK-wide partnership* of funders that works to coordinate research related to cancer, to improve the quality and relevance of research and to accelerate translation of the research into clinical practice for the benefit of patients.
Media can register by email: firstname.lastname@example.org
We welcome the media to the Conference. Every session is open to journalists and registration is free of charge to journalists who are in possession of a valid, recognised press card. Freelance journalists must present a commissioning letter on headed paper from a recognised news organisation or publication. Copies of the credentials and identification will be requested at the time of registration and when journalists arrive at the Conference. Business cards are NOT acceptable. Full details can be found in the media policy: https:/
For media queries about the Conference, contact Kerry Noble or Emma Mason, media consultants:
Tel: +44 (0)7446 869 433
More information on the programme is available on the NCRI Cancer Conference website at: https:/
Information on accommodation in Glasgow can be found here:
Reservations are made on a first-come, first-served basis and participants are advised to book early.
*NCRI Partners are: Biotechnology and Biological Sciences Research Council (BBSRC); Bloodwise; Brain Tumour Research, Breast Cancer Now; Cancer Research UK; Children with Cancer UK, Department of Health and Social Care; Economic and Social Research Council (ESRC); Macmillan Cancer Support; Marie Curie; Medical Research Council (MRC); Northern Ireland Health and Social Care Public Health Agency (Research & Development Department); Pancreatic Cancer Research Fund; Prostate Cancer UK; Roy Castle Lung Cancer Foundation; Scottish Government Health Directorates (Chief Scientist Office); Tenovus Cancer Care; The Wellcome Trust and Welsh Assembly Government (Health and Care Research Wales)
For more information visit http://www.